Enlivex Therapeutics Ltd (ENLV)

Enlivex (ENLV) Stock Price & Analysis


ENLV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.27 - $4.65
Previous Close$1.8
Average Volume (3M)31.72K
Market Cap
Enterprise Value-$12.59M
Total Cash (Recent Filing)$50.24M
Total Debt (Recent Filing)$4.19M
Price to Earnings (P/E)-1.2
May 24, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding18,420,000
10 Day Avg. Volume15,096
30 Day Avg. Volume31,717
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.72
Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Ownership Overview

0.06% Mutual Funds
0.49% Other Institutional Investors
99.46% Public Companies and
Individual Investors


What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.27 and its highest was $4.65 in the past 12 months.
    What is Enlivex Therapeutics Ltd’s market cap?
    Currently, no data Available
    When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
    Enlivex Therapeutics Ltd’s upcoming earnings report date is May 24, 2024 which is in 173 days.
      How were Enlivex Therapeutics Ltd’s earnings last quarter?
      Enlivex Therapeutics Ltd released its earnings results on Nov 20, 2023. The company reported -$0.32 earnings per share for the quarter, the consensus estimate of -$0.32 by $0.
        Is Enlivex Therapeutics Ltd overvalued?
        According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Enlivex Therapeutics Ltd pay dividends?
          Enlivex Therapeutics Ltd does not currently pay dividends.
          What is Enlivex Therapeutics Ltd’s EPS estimate?
          Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Enlivex Therapeutics Ltd have?
          Enlivex Therapeutics Ltd has 18,589,140 shares outstanding.
            What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
            Enlivex Therapeutics Ltd reported an EPS of -$0.32 in its last earnings report, expectations of -$0.32. Following the earnings report the stock price went down -1.724%.
              Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
              Among the largest hedge funds holding Enlivex Therapeutics Ltd’s share is ARK Investment Management LLC. It holds Enlivex Therapeutics Ltd’s shares valued at N/A.


                Company Description

                Enlivex Therapeutics Ltd

                Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Apellis Pharmaceuticals
                Seres Therapeutics
                Karuna Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis